Compare ACRV & DIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACRV | DIT |
|---|---|---|
| Founded | 2018 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Food Distributors |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.5M | 79.1M |
| IPO Year | 2022 | 1996 |
| Metric | ACRV | DIT |
|---|---|---|
| Price | $1.51 | $66.00 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $11.67 | N/A |
| AVG Volume (30 Days) | ★ 441.3K | 4.5K |
| Earning Date | 05-08-2026 | 04-20-2026 |
| Dividend Yield | N/A | ★ 0.74% |
| EPS Growth | ★ 15.13 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,392,388,157.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $568.17 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 5.30 |
| 52 Week Low | $1.20 | $59.15 |
| 52 Week High | $3.56 | $122.00 |
| Indicator | ACRV | DIT |
|---|---|---|
| Relative Strength Index (RSI) | 36.38 | 36.49 |
| Support Level | $1.38 | N/A |
| Resistance Level | $2.20 | $73.33 |
| Average True Range (ATR) | 0.13 | 1.06 |
| MACD | -0.05 | -0.00 |
| Stochastic Oscillator | 0.78 | 41.26 |
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.
Amcon Distributing Co is engaged in the wholesale and retail distribution of consumer products such as cigarettes, tobacco, confectionery, health food, and others. It operates in two segments: Wholesale distribution segment distributing consumer products to the retail outlets including convenience stores, grocery stores, liquor stores, drug stores and tobacco shops in the Central, Rocky Mountain, and Southern regions of the United States; and the Retail health food segment is a specialty retailer of natural/organic groceries and dietary supplements throughout the Midwest and Florida. The company earns a majority of the revenue from the Wholesale distribution segment.